Management strategy of 1L Lorlatinib with Hyperlipidemia in Stage IIIB-IV ALK positive NSCLC: A multi-center prospective study in China (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1041eTiP; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK
|
|
Shen Zhao; Yunpeng Yang; Yan Huang; Hongyun Zhao; Yuan Liang; Di Wu; Fengying Wu; Aiguo Xu; Runxiang Yang; Yu Yao; Jian Zhang; Li Zhang
|